Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

SnapshotDx Quiz: January 2018

Cynthia X Wang¹, Milan J Anadkat²

¹Washington University School of Medicine, St Louis, Missouri.

The Journal of Investigative Dermatology

|December 24, 2017

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial.

The British journal of dermatology·2025

Same author

The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trial.

Journal of the American Academy of Dermatology·2025

Same author

Clinical, Radiologic, and Optical Coherence Tomographic Features of Pediatric Acute Disseminated Encephalomyelitis: Comparison of Myelin Oligodendrocyte Glycoprotein Antibody-Positive and -Negative Cases.

Pediatric neurology·2025

Same author

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares.

The Journal of clinical investigation·2025

Same author

Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Dermatology and therapy·2025

Same author

Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Dermatology and therapy·2025